Skip to main content
Top
Published in: Clinical & Experimental Metastasis 4/2020

01-08-2020 | Colon Cancer | Research Paper

Mass spectrometry-based proteomic capture of proteins bound to the MACC1 promoter in colon cancer

Authors: Yahui Huang, Yi Xiang, Zhongpeng Xie, Yuxiang Cai, Qiongzhi Yang, Huichao Huang, Zhuchu Chen, Zhefeng Xiao, Qiongqiong He

Published in: Clinical & Experimental Metastasis | Issue 4/2020

Login to get access

Abstract

MACC1 (metastasis associated in colon cancer 1) is a key driver that induces metastasis in colon cancer. However, the mechanisms by which MACC1 expression is transcriptionally regulated and the factors enriched at the MACC1 promoter remain largely unknown. The binding of proteins to specific DNA sites in the genome is a major determinant of genomic maintenance and the regulation of specific genes. The study herein utilized two methods to study the binding proteins of the MACC1 promoter region in colon cancer. Specifically, we adopted CRISPR-based chromatin affinity purification with mass spectrometry (CRISPR-ChAP-MS) and a biotin-streptavidin pulldown assay coupled with MS to identify the specific proteome bound to the MACC1 promoter in two colon cell lines with different metastatic potential. A total of 24 proteins were identified by CRISPR-ChAP-MS as binding to the MACC1 promoter, among which c-JUN was validated by ChIP-PCR. A total of 739 binding protein candidates were identified by biotin-streptavidin pulldown assays coupled with MS, of which HNF4G and PAX6 were validated and compared for their binding to the same promoter sites in the two cell lines. Our studies suggest distinctive proteomic factors associated with the MACC1 promoter in colon cells with different metastatic potential. The dynamic regulatory factors accumulated at the promoter of MACC1 may provide novel insights into the regulatory mechanisms of MACC1 transcription.
Appendix
Available only for authorised users
Literature
2.
go back to reference Byrum SD et al (2012) ChAP-MS: a method for identification of proteins and histone posttranslational modifications at a single genomic locus. Cell Rep 2(1):198–205PubMedPubMedCentralCrossRef Byrum SD et al (2012) ChAP-MS: a method for identification of proteins and histone posttranslational modifications at a single genomic locus. Cell Rep 2(1):198–205PubMedPubMedCentralCrossRef
5.
6.
go back to reference Mittler G, Butter F, Mann M (2009) A SILAC-based DNA protein interaction screen that identifies candidate binding proteins to functional DNA elements. Genome Res 19(2):284–293PubMedPubMedCentralCrossRef Mittler G, Butter F, Mann M (2009) A SILAC-based DNA protein interaction screen that identifies candidate binding proteins to functional DNA elements. Genome Res 19(2):284–293PubMedPubMedCentralCrossRef
8.
go back to reference Viturawong T et al (2013) A DNA-centric protein interaction map of ultraconserved elements reveals contribution of transcription factor binding hubs to conservation. Cell Rep 5(2):531–545PubMedCrossRef Viturawong T et al (2013) A DNA-centric protein interaction map of ultraconserved elements reveals contribution of transcription factor binding hubs to conservation. Cell Rep 5(2):531–545PubMedCrossRef
9.
go back to reference Butter F et al (2012) Proteome-wide analysis of disease-associated SNPs that show allele-specific transcription factor binding. PLoS Genet 8(9):e1002982PubMedPubMedCentralCrossRef Butter F et al (2012) Proteome-wide analysis of disease-associated SNPs that show allele-specific transcription factor binding. PLoS Genet 8(9):e1002982PubMedPubMedCentralCrossRef
10.
go back to reference Spruijt CG et al (2013) Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives. Cell 152(5):1146–1159PubMedCrossRef Spruijt CG et al (2013) Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives. Cell 152(5):1146–1159PubMedCrossRef
11.
go back to reference Fujita T, Fujii H (2013) Efficient isolation of specific genomic regions and identification of associated proteins by engineered DNA-binding molecule-mediated chromatin immunoprecipitation (enChIP) using CRISPR. Biochem Biophys Res Commun 439(1):132–136PubMedCrossRef Fujita T, Fujii H (2013) Efficient isolation of specific genomic regions and identification of associated proteins by engineered DNA-binding molecule-mediated chromatin immunoprecipitation (enChIP) using CRISPR. Biochem Biophys Res Commun 439(1):132–136PubMedCrossRef
12.
go back to reference Fujita T, Fujii H (2014) Identification of proteins associated with an IFNgamma-responsive promoter by a retroviral expression system for enChIP using CRISPR. PLoS ONE 9(7):e103084PubMedPubMedCentralCrossRef Fujita T, Fujii H (2014) Identification of proteins associated with an IFNgamma-responsive promoter by a retroviral expression system for enChIP using CRISPR. PLoS ONE 9(7):e103084PubMedPubMedCentralCrossRef
13.
go back to reference Hamidian A et al (2018) Promoter-associated proteins of EPAS1 identified by enChIP-MS—a putative role of HDX as a negative regulator. Biochem Biophys Res Commun 499(2):291–298PubMedCrossRef Hamidian A et al (2018) Promoter-associated proteins of EPAS1 identified by enChIP-MS—a putative role of HDX as a negative regulator. Biochem Biophys Res Commun 499(2):291–298PubMedCrossRef
14.
go back to reference Mochizuki Y et al (2018) Combinatorial CRISPR/Cas9 approach to elucidate a far-upstream enhancer complex for tissue-specific Sox9 expression. Dev Cell 46(6):794–806.e6PubMedPubMedCentralCrossRef Mochizuki Y et al (2018) Combinatorial CRISPR/Cas9 approach to elucidate a far-upstream enhancer complex for tissue-specific Sox9 expression. Dev Cell 46(6):794–806.e6PubMedPubMedCentralCrossRef
15.
go back to reference Stein U et al (2009) MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 15(1):59–67PubMedCrossRef Stein U et al (2009) MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 15(1):59–67PubMedCrossRef
16.
go back to reference Radhakrishnan H et al (2018) MACC1-the first decade of a key metastasis molecule from gene discovery to clinical translation. Cancer Metastasis Rev 37(4):805–820PubMedCrossRef Radhakrishnan H et al (2018) MACC1-the first decade of a key metastasis molecule from gene discovery to clinical translation. Cancer Metastasis Rev 37(4):805–820PubMedCrossRef
17.
18.
go back to reference Juneja M et al (2013) Promoter identification and transcriptional regulation of the metastasis gene MACC1 in colorectal cancer. Mol Oncol 7(5):929–943PubMedPubMedCentralCrossRef Juneja M et al (2013) Promoter identification and transcriptional regulation of the metastasis gene MACC1 in colorectal cancer. Mol Oncol 7(5):929–943PubMedPubMedCentralCrossRef
19.
go back to reference Kuo IY et al (2014) Low SOX17 expression is a prognostic factor and drives transcriptional dysregulation and esophageal cancer progression. Int J Cancer 135(3):563–573PubMedCrossRef Kuo IY et al (2014) Low SOX17 expression is a prognostic factor and drives transcriptional dysregulation and esophageal cancer progression. Int J Cancer 135(3):563–573PubMedCrossRef
20.
go back to reference Deng WG et al (2006) Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Blood 108(2):518–524PubMedPubMedCentralCrossRef Deng WG et al (2006) Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Blood 108(2):518–524PubMedPubMedCentralCrossRef
22.
go back to reference Foulds CE et al (2013) Proteomic analysis of coregulators bound to ERalpha on DNA and nucleosomes reveals coregulator dynamics. Mol Cell 51(2):185–199PubMedPubMedCentralCrossRef Foulds CE et al (2013) Proteomic analysis of coregulators bound to ERalpha on DNA and nucleosomes reveals coregulator dynamics. Mol Cell 51(2):185–199PubMedPubMedCentralCrossRef
23.
go back to reference Sharma NL et al (2014) The ETS family member GABPalpha modulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancer. Nucleic Acids Res 42(10):6256–6269PubMedPubMedCentralCrossRef Sharma NL et al (2014) The ETS family member GABPalpha modulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancer. Nucleic Acids Res 42(10):6256–6269PubMedPubMedCentralCrossRef
25.
go back to reference Mascarenhas JB et al (2009) PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene. J Biol Chem 284(40):27524–27532PubMedPubMedCentralCrossRef Mascarenhas JB et al (2009) PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene. J Biol Chem 284(40):27524–27532PubMedPubMedCentralCrossRef
27.
go back to reference Li Y et al (2014) PAX6, a novel target of microRNA-7, promotes cellular proliferation and invasion in human colorectal cancer cells. Dig Dis Sci 59(3):598–606PubMedCrossRef Li Y et al (2014) PAX6, a novel target of microRNA-7, promotes cellular proliferation and invasion in human colorectal cancer cells. Dig Dis Sci 59(3):598–606PubMedCrossRef
Metadata
Title
Mass spectrometry-based proteomic capture of proteins bound to the MACC1 promoter in colon cancer
Authors
Yahui Huang
Yi Xiang
Zhongpeng Xie
Yuxiang Cai
Qiongzhi Yang
Huichao Huang
Zhuchu Chen
Zhefeng Xiao
Qiongqiong He
Publication date
01-08-2020
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 4/2020
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-020-10045-z

Other articles of this Issue 4/2020

Clinical & Experimental Metastasis 4/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine